Interpace Diagnostics Group (IDXG) Stock Rating Upgraded by ValuEngine

Interpace Diagnostics Group (NASDAQ:IDXG) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Friday.

Separately, Maxim Group reaffirmed a “buy” rating and set a $5.00 price objective on shares of Interpace Diagnostics Group in a report on Tuesday, November 14th.

Shares of Interpace Diagnostics Group (IDXG) opened at $1.00 on Friday. Interpace Diagnostics Group has a fifty-two week low of $0.72 and a fifty-two week high of $4.45. The stock has a market cap of $26.85, a price-to-earnings ratio of 0.35 and a beta of 1.64.

Interpace Diagnostics Group (NASDAQ:IDXG) last posted its quarterly earnings data on Monday, November 13th. The business services provider reported ($0.15) earnings per share (EPS) for the quarter. Interpace Diagnostics Group had a negative return on equity of 5.69% and a negative net margin of 6.33%. The company had revenue of $4.20 million for the quarter.

An institutional investor recently bought a new position in Interpace Diagnostics Group stock. Sabby Management LLC acquired a new position in shares of Interpace Diagnostics Group Inc (NASDAQ:IDXG) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 529,819 shares of the business services provider’s stock, valued at approximately $476,000. Sabby Management LLC owned about 2.39% of Interpace Diagnostics Group as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 5.69% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Interpace Diagnostics Group (IDXG) Stock Rating Upgraded by ValuEngine” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with's FREE daily email newsletter.

Leave a Reply